Moderna shares fall again after another steep drop, while Merck and Pfizer also slip on personalized melanoma vaccine trading

Moderna’s stock extended its slide on October 23, according to market coverage, after the shares fell sharply earlier in the session. The report described Moderna as down about 4% following an approximately 18% plunge, pointing to continuing pressure after renewed attention on a personalized melanoma vaccine program.

The catalyst discussed in the coverage was the release of late-stage results for the personalized melanoma vaccine backed by Moderna. The article characterized those results as positive, but said selling continued anyway, suggesting the market’s expectations for the program were even higher than what investors saw in the readout.

The same market move also showed up in large-cap peers tied to oncology and vaccines. The report said Merck and Pfizer were also slipping, implying that the melanoma vaccine news was broad enough to influence sentiment across multiple investors’ portfolios, not just the company leading the personalized approach.

The trading reaction underscores a recurring pattern in late-stage biotech catalysts: even favorable efficacy or response indicates may not be enough if investors interpret the data as short of the most optimistic thresholds, or if the next milestones and commercial implications remain uncertain. In this case, the coverage explicitly linked the continuing selloff to a mismatch between the “positive” results and the market’s loftiest hopes.

For Moderna, a personalized melanoma vaccine is a biologic that aims to tailor treatment to a patient’s specific cancer features rather than relying on a one-size-fits-all product. That personalization can be scientifically and operationally attractive, but it can also introduce added complexity that investors may want clarified, such as manufacturing scalability, patient turnaround times, and how outcomes compare with existing standards of care.

For Merck and Pfizer, the connection is less direct in the article’s framing, but the price action suggests the market treated the melanoma catalyst as relevant to broader oncology and vaccine expectations. When investors see late-stage readouts in a high-profile area, they may re-evaluate timelines, competitive differentiation, and probability-weighted prospects across the sector, even if only one company is the lead developer of the specific program mentioned.

What remains unclear from the coverage alone is the depth of the results, including the magnitude of benefit, the specific endpoints reported, and whether safety or subgroup findings affected investor interpretation. The article’s framing indicates “positive” outcomes, but it does not provide enough detail here to determine which aspects were most influential to the selloff or whether the data changed guidance, timelines, or regulatory expectations.